- Drugs
- Friday, 22 May 2020
Hikma receives FDA approval for its generic Vascepa®
Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has announced that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa®1.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa® patents owned by Amarin. The District Court decision is currently being appealed.
Brian Hoffmann, President of Generics said, "The approval for our generic version of Vascepa® is an important milestone towards bringing this product to market. This approval demonstrates the strength of our regulatory capabilities and our commitment to provide patients and healthcare providers in the US with the high-quality medicines they need."
| Enquiries | |
| Hikma Pharmaceuticals PLC | |
| Susan Ringdal | +44 (0)20 7399 2760/ +44 7776 477050 |
| EVP, Strategic Planning and Global Affairs | |
| Steve Weiss | +1 732 720 2830/ +1 732 788 8279 |
| David Belian | +1 732 720 2814/+1 848 254 4875 |
| US Communications and Public Affairs |
Related Industry Updates
Zongertinib Gains Accelerated FDA Approval as First Oral Targeted Option for HER2-Mutant Lung Cancer
Aug 26, 2025
Human Vaccine Adjuvants Market is expected to reach US$ 4,489.23 million by 2030
Jan 04, 2024
Autoimmune Diseases: Prevalence, Diagnosis, and Treatment Advances
Feb 10, 2026
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Feb 13, 2020
GeneQuantum Healthcare (GQ) receives IND clearance by the US FDA for ADC drug
Jun 11, 2020
Rx Green Technologies Launches New Clean Coco Coir Products
May 05, 2020
Genentech’s Fenebrutinib Shows Breakthrough MS Results
Feb 16, 2026
Follow us on
